In accordance with the legislation of the Czech Republic, the Company provides services only to qualified investors!

Vor Biopharma. Financial results for the second quarter of 2021.

10.08.2021

GAAP net loss is -$0.50, which is $0.07 better than the same period last year.

Cash, cash equivalents and investments are $244.6 million as of June 30, 2021.